Colorectal cancer screening† Colorectal cancer or adenomatous polyps in first-degree relative younger than age 60 years or in two or more first-degree relatives of any ages; family history of familial adenomatous polyposis or hereditary non-polyposis colon cancer; history of colorectal cancer, adenomatous polyps, inﬂammatory bowel disease, chronic ulcerative colitis, or Crohn’s disease
Diphtheria and reduced tetanus Adults who have or who anticipate having close contact with an infant aged less than 12 toxoids and acellular pertussis months and health care providers. When possible, women should receive Tdap before vaccine‡ becoming pregnant.
Fasting glucose testing§ Overweight (BMI greater than or equal to 25); first-degree relative with diabetes mellitus; habitual physical inactivity; high-risk race or ethnicity (eg, African American, Latina, Native American, Asian American, Pacific Islander); have given birth to a newborn weighing more than 9 lb or have a history of gestational diabetes mellitus; hypertension; high-density lipoprotein cholesterol level less than 35 mg/dL; triglyceride level greater than 250 mg/dL; history of impaired glucose tolerance or impaired fasting glucose; polycystic ovary syndrome; history of vascular disease; other clinical conditions associated with insulin resistance
Fluoride supplementation Live in area with inadequate water ﬂuoridation (less than 0.7 ppm)
Genetic testing/counseling Considering pregnancy and: patient, partner, or family member with history of genetic disorder or birth defect; exposure to teratogens; or African, Cajun, Caucasian, European, Eastern European (Ashkenazi) Jewish, French Canadian, Mediterranean, or Southeast Asian ancestry
Hemoglobin level assessment Caribbean, Latin American, Asian, Mediterranean, or African ancestry; history of excessive menstrual ﬂow
HAV vaccination Chronic liver disease, clotting factor disorders, illegal drug user, individuals who work with HAV-infected nonhuman primates or with HAV in a research laboratory setting, individuals traveling to or working in countries that have high or intermediate endemicity of hepatitis A
HBV vaccination Hemodialysis patients; patients who receive clotting factor concentrates; health care workers and public safety workers who have exposure to blood in the workplace; individuals in training in schools of medicine, dentistry, nursing, laboratory technology, and other allied health professions; injecting drug users; individuals with more than one sexual partner in the previous 6 months; individuals with a recently acquired STD; all clients in STD clinics; household contacts and sexual partners of individuals with chronic HBV infection; clients and staff of institutions for the developmentally disabled; international travelers who will be in countries with high or intermediate prevalence of chronic HBV infection for more than 6 months; inmates of correctional facilities
HCV testing History of injecting illegal drugs, recipients of clotting factor concentrates before 1987, chronic (long-term) hemodialysis, persistently abnormal alanine aminotransferase levels, recipients of blood from donors who later tested positive for HCV infection, recipients of blood or blood-component transfusion or organ transplant before July 1992, occupational percutaneous or mucosal exposure to HCV-positive blood